Regeneron Pharma (REGN) PT Lowered to $1,013 at Piper Sandler as Eylea HD Revenue Misses Consensus
Tweet Send to a Friend
Piper Sandler analyst Christopher Raymond lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $1,013.00 (from $1,195.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
